Skip to main content

Table 1 Transmission of tissue isolates (10% cerebral/cerebellar cortex homogenates from hGH-iCJD cases) into mice expressing the human PrP (methionine, valine, at codon 129)

From: Prion strains associated with iatrogenic CJD in French and UK human growth hormone recipients

Isolate number

Cases

Brain area

Codon 129

Origin

Year

Age

Incub period

1

MM

Fr

2001

31

16

Cort

2

Fr

2006

39

21

Cort

3

Fr

2006

36

23

Cort

4

Fr

2003

33

20

Cereb

5

Fr

2004

35

21

Cort

6

UK

2011

46

29

Cort

7

UK

2012

42

32

Cort

8

MV

UK

2001

30

20

Cort

9

UK

1999

37

19

Cort

10

Fr

2006

38

25

Cort

11

Fr

2008

27

24

Cereb

12

Fr

2003

35

23

Cereb

13

UK

1990

34

17

Cort

14

VV

UK

1998

27

16

Cort

15

UK

1997

36

19

Cort

16

UK

1995

33

18

Cort

17

UK

1994

25

11

Cort

18

Fr

1991

11

5

Cort

19

Fr

2000

27

16

Cort

20

UK

1993

30

13

Cort

21

UK

1992

31

16

Cort

22

Fr

1999

24

15

Cort

Isolate number

TgMet129

TgVal129

Passage 1

Passage 2

Passage3

Passage 1

Passage 2

Survival time (mean ± SD)

PrPres

Survival time (mean ± SD)

PrPres

Survival time (mean ± SD)

PrPres

Survival time (mean ± SD)

PrPres

Survival time (mean ± SD)

PrPres

1

585 ± 29

1

487 ± 34

1

ND

 

173 ± 3

2

171 ± 2

2

2

582 ± 81

1

492 ± 57

1

ND

 

162 ± 3

2

179 ± 7

2

3

569 ± 76

1

> 400*

   

163 ± 7

2

181 ± 11

2

4

593 ± 118

1

298 ± 61

1

206 ± 9

1

195 ± 13

2

165 ± 3

2

5

453 ± 137

1

204 ± 4

1

ND

 

180 ± 6

2

174 ± 9

2

6

246 ± 33

1

213 ± 10

1

ND

 

206 ± 6

2

161 ± 3

2

7

230 ± 5

1

193 ± 6

1

ND

 

313 ± 5

1

271 ± 5

1

8

562 ± 55

1

456 ± 6

1

ND

 

211 ± 12

2

173 ± 7

2

9

635 ± 66

1

503 ± 19

1

ND

 

172 ± 10

2

177 ± 7

2

10

525 ± 32

1

488 ± 31

1

ND

 

188 ± 15

2

169 ± 10

2

11

511 ± 29

1

> 400*

1

ND

 

164 ± 5

2

166 ± 9

2

12

566 ± 170

1

299 ± 42

1

194 ± 4

1

160 ± 10

2

163 ± 4

2

13

337 ± 66

1

212 ± 13

1

ND

 

193 ± 5

2

176 ± 15

2

14

626 ± 57

1

613 ± 21

1

ND

 

176 ± 9

2

ND

2

15

423 ± 23

1

669 ± 56

1

ND

 

180 ± 9

2

175 ± 5

2

16

665 ± 15

1

484 ± 30

1

ND

 

165 ± 5

2

175 ± 14

2

17

628 ± 83

1

568 ± 82

1

ND

 

198 ± 7

2

169 ± 7

2

18

565 ± 19

1

> 400*

1

  

165 ± 5

2

180 ± 10

2

19

759 ± 64

1

> 400*

1

  

171 ± 7

2

177 ± 8

2

20

612 ± 122

1

312 ± 49

1

202 ± 4

1

178 ± 7

2

180 ± 7

2

21

446 ± 165

1

210 ± 12

1

ND

 

194 ± 7

2

170 ± 3

2

22

362 ± 48

1

229 ± 8

1

ND

 

439**

1

ND

 
  1. Transgenic mice that express the Met129 (tgMet), Val129 (tgVal) human PrP were inoculated intra-cerebrally (20µL per mouse) with human growth hormone (hGH) iatrogenic Creutzfeldt–Jakob brain tissue homogenates (frontal, temporal or parietal cortex: (cort) or cerebrellar cortex: (cereb)) from patients originating (orig.) from France (Fr), or the United Kingdom (UK). The hGH-iCJD patients displayed different PRNP genotypes at codon 129 (MM: homozygous Met129, VV: homozygous Val129, MV: heterozygous Met/Val129). For each patient, the country of origin, the year of death and age in years at death are indicated. The estimated duration of the incubation period in years (based on the hGH treatment history) is also indicated. After the first and second passages, brain tissue from the clinically affected mice were pooled and used for a next passage in the same line. The PrPres WB isoforms (type 1 or type 2) identified in mouse brains are reported for each two passages. Survival times are shown as mean ± standard deviation (SD). 100% attack rate transmission were observed in all cases
  2. ND not done
  3. *Transmission still ongoing with no dead animals observed at the reported date
  4. **A single inoculated animal was positive